Bristol-Myers Squibb and Pfizer entered into exclusive worldwide collaboration to develop and commercialize the anticoagulant apixaban, which is in different clinical trials for treating arterial and venous thrombotic conditions. The deal would worth up to US$1 B to Bristol-Meyers Squibb.